1-Boc-3-Hydroxypiperidine acts as a reagent in the preparation of AZD8931, an equipotent, reversible inhibitor of signalling by EGFR, HER2, and HER3 receptors which is being clinically evaluated for the treatment of cancer.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.